Target intelligence / Profile preview

AT-rich DNA minor groove motifs at PU.1 ETS binding sites (PU.1 EBS)

Target
PU.1 EBS
Molecular classification
DNA motif, Transcription factor binding site, Regulatory element
01

Overview

The AT-rich DNA minor groove motifs at PU.1 ETS binding sites are specific genomic sequences that serve as critical docking points for the PU.1 (SPI1) transcription factor, a master regulator of myeloid and B-cell development (Antony-Debré et al., 2017, J Clin Invest). In diseases like acute myeloid leukemia (AML), PU.1 activity is often dysregulated, contributing to a block in cell differentiation and uncontrolled proliferation. These minor groove motifs are targeted by specialized small molecules, such as heterocyclic diamidines, which bind with high affinity to the AT-rich regions adjacent to the 5'-GGAA-3' core sequence. This interaction effectively displaces PU.1 from its cognate DNA sites, leading to the downregulation of oncogenic gene expression programs and the induction of terminal differentiation in leukemic blasts (Stephens et al., 2016, FEBS J). Beyond oncology, PU.1 binding sites are also investigated in neuroinflammatory contexts, such as Alzheimer's disease, where PU.1 regulates microglial activation. Targeting the DNA-protein interface at these motifs represents a precision medicine approach to modulating 'undruggable' transcription factors.

Other names
PU.1 binding siteSPI1 binding siteETS binding site minor groovePU.1-DNA interfaceAT-rich flanking sequences of PU.1 EBS
02

Mechanism of action

Small molecule binding to the DNA minor groove at AT-rich sequences flanking the PU.1 core binding site, resulting in competitive or allosteric inhibition of PU.1 transcription factor recruitment (Munde et al., 2014, Nucleic Acids Res).

03

Biological functions

HematopoiesisMyeloid differentiationB-cell developmentGene expression regulationMicroglial activation
04

Disease associations

Acute Myeloid LeukemiaAlzheimer's diseaseSystemic Lupus ErythematosusInflammation
05

Safety considerations

Potential off-target binding to other AT-rich DNA sequencesInhibition of other ETS-family transcription factorsGeneral genotoxicity associated with DNA-binding agentsSuppression of normal hematopoietic stem cell function
06

Interacting drugs

DB1976

2 more in the full profile.

07

Biomarkers

PU.1 (SPI1) mRNA expressionCD11b protein expressionCD14 protein expressionSPI1 genomic translocations

Beyond the preview

Go deeper on AT-rich DNA minor groove motifs at PU.1 ETS binding sites (PU.1 EBS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-rich DNA minor groove motifs at PU.1 ETS binding sites (PU.1 EBS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call